In the multiple-dose study, 16 AEs reported by seven subjects in the cefiderocol 1,000-mg 1st group were considered possibly or probably related to the study treatment: rash (5 events in five subjects), a blood thyroid-stimulating hormone (TSH) level increase (3 events in three subjects), pyrexia (2 events in two subjects), and 1 event each of an alanine aminotransferase level increase, an aspartate aminotransferase level increase, a blood TSH level decrease, a blood urea level increase, urine present in blood, and headache. The gene discussed is GPT; the disease is Fever.